VBI
鑫品生醫科技股份有限公司
VBI is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is AlloStim (Phase 2 in the US; Taiwan co-development and sales agency, Liver cancer), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| AlloStim | — | Phase 2 in the US; Taiwan co-development and sales agency | Liver cancer | United States (clinical trial) | 2026-04-30 | Company disclosure |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.